Van ECK Associates Corp grew its stake in shares of Blueprint Medicines by 16.0% in the first quarter. Exane Derivatives now owns 567 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 178 shares during the last quarter. Exane Derivatives grew its stake in shares of Blueprint Medicines by 45.8% in the first quarter. CIBC Asset Management Inc now owns 2,536 shares of the biotechnology company’s stock worth $272,000 after purchasing an additional 168 shares during the last quarter. CIBC Asset Management Inc grew its stake in shares of Blueprint Medicines by 7.1% in the fourth quarter. now owns 906 shares of the biotechnology company’s stock worth $97,000 after buying an additional 150 shares during the last quarter. grew its stake in shares of Blueprint Medicines by 19.8% during the fourth quarter. Institutional Trading of Blueprint MedicinesĪ number of hedge funds and other institutional investors have recently modified their holdings of the stock. Corporate insiders own 3.42% of the company’s stock. In the last 90 days, insiders sold 34,408 shares of company stock worth $2,334,022.
The disclosure for this sale can be found here. Following the completion of the sale, the director now owns 183,243 shares of the company’s stock, valued at $12,839,837.01. The shares were sold at an average price of $70.07, for a total transaction of $700,700.00. Albers sold 10,000 shares of Blueprint Medicines stock in a transaction that occurred on Monday, August 8th. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Following the completion of the sale, the director now directly owns 183,243 shares in the company, valued at $12,535,653.63.
The shares were sold at an average price of $68.41, for a total transaction of $1,368,200.00. Albers sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. In other Blueprint Medicines news, Director Jeffrey W. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Following the completion of the transaction, the director now owns 183,243 shares in the company, valued at approximately $12,839,837.01. The stock was sold at an average price of $70.07, for a total transaction of $700,700.00. Albers sold 10,000 shares of the stock in a transaction dated Monday, August 8th. As a group, sell-side analysts forecast that Blueprint Medicines will post -9.17 EPS for the current fiscal year. During the same quarter last year, the company posted ($1.86) earnings per share. The business’s quarterly revenue was up 33.9% compared to the same quarter last year. Blueprint Medicines had a negative return on equity of 45.89% and a negative net margin of 304.41%. The business had revenue of $36.55 million for the quarter, compared to analysts’ expectations of $37.61 million.
The biotechnology company reported ($2.68) earnings per share for the quarter, missing the consensus estimate of ($2.23) by ($0.45). Get Blueprint Medicines alerts:īlueprint Medicines ( NASDAQ:BPMC – Get Rating) last released its earnings results on Tuesday, August 2nd. According to, the company currently has an average rating of Moderate Buy and a consensus price target of $90.67. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Finally, upgraded Blueprint Medicines from a sell rating to a hold rating in a report on Monday, May 9th. The Goldman Sachs Group boosted their price objective on Blueprint Medicines from $126.00 to $143.00 and gave the stock a buy rating in a research note on Wednesday, August 3rd. They issued an underweight rating and a $40.00 price objective on the stock. Wells Fargo & Company began coverage on Blueprint Medicines in a research note on Monday, June 27th. Piper Sandler cut their target price on Blueprint Medicines from $65.00 to $59.00 in a research note on Tuesday, August 2nd. HC Wainwright dropped their target price on Blueprint Medicines from $100.00 to $80.00 and set a buy rating on the stock in a report on Wednesday, August 17th. Several other equities research analysts also recently commented on the company. Blueprint Medicines ( NASDAQ:BPMC – Get Rating) had its price target hoisted by Jefferies Financial Group from $78.00 to $84.00 in a research note issued to investors on Monday, The Fly reports.
0 kommentar(er)
